Answers are grounded in this paper and cite their sources.
The continued evolution of bacterial resistance to the β-lactam class of antibiotics has necessitated countermeasures to ensure continued effectiveness in the treatment of infections caused by bacterial pathogens. One relatively successful approach has been the development of new β-lactam analogs with advantages over prior compounds in this class. The carbapenems are an example of such β-lactam analogs possessing improved stability against β-lactamase enzymes and, therefore, a wider spectrum of activity.
No takes yet. Share an insight, caveat, or question.
Cotroneo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: